Vitro Biopharma, Inc. financial data

Industry
Biological Products, (No Diagnostic Substances)
Location
3200 Cherry Creek Drive South, Suite 410, Denver, CO
State of incorporation
NV
Fiscal year end
October 31
Former names
VITRO DIAGNOSTICS INC (to 10/20/2021)
Latest financial report
10-Q - Q4 2024 - Mar 20, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 12.6 % -78.2%
Quick Ratio 1.55 % -58.9%
Debt-to-equity -169 % +79.1%
Return On Assets -139 % -31.1%
Operating Margin -326 % +34.1%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 4.46M shares 0%
Common Stock, Shares, Outstanding 4.46M shares 0%
Entity Public Float 0 USD
Common Stock, Value, Issued 4.46K USD 0%
Weighted Average Number of Shares Outstanding, Basic 4.46M shares +0.12%
Weighted Average Number of Shares Outstanding, Diluted 4.46M shares +0.12%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 1.88M USD +2.04%
Revenue from Contract with Customer, Excluding Assessed Tax 1.88M USD +2.08%
Research and Development Expense 536K USD +50.6%
Operating Income (Loss) -6.12M USD +32.8%
Net Income (Loss) Attributable to Parent -8.14M USD +6.83%
Earnings Per Share, Basic -1.82 USD/shares +7.61%
Earnings Per Share, Diluted -1.82 USD/shares +7.61%

Balance Sheet

Label TTM Value / Value Unit Change %
Accounts Receivable, after Allowance for Credit Loss, Current 206K USD +72.4%
Inventory, Net 161K USD -1.22%
Assets, Current 409K USD -82.1%
Property, Plant and Equipment, Net 102K USD -63.1%
Operating Lease, Right-of-Use Asset 315K USD -28.8%
Intangible Assets, Net (Excluding Goodwill) 350K USD -46.2%
Goodwill 3.17M USD -12.1%
Other Assets, Noncurrent 8.44K USD 0%
Assets 4.45M USD -39.6%
Accounts Payable, Current 2.44M USD +10.7%
Accrued Liabilities, Current 1.86M USD +23.4%
Liabilities, Current 12.7M USD +58.4%
Operating Lease, Liability, Noncurrent 198K USD -37.1%
Liabilities 14.4M USD +17.8%
Retained Earnings (Accumulated Deficit) -40.8M USD -24.9%
Stockholders' Equity Attributable to Parent -9.91M USD -105%
Liabilities and Equity 4.45M USD -39.6%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -428K USD +64.3%
Net Cash Provided by (Used in) Financing Activities -29.2K USD -101%
Net Cash Provided by (Used in) Investing Activities -74 USD +84.8%
Common Stock, Shares Authorized 19.2M shares 0%
Common Stock, Shares, Issued 4.46M shares 0%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 114K USD -94%
Interest Paid, Excluding Capitalized Interest, Operating Activities 4.22K USD -13.8%
Deferred Tax Assets, Valuation Allowance 7.44M USD +47.3%
Deferred Tax Assets, Gross 7.44M USD +47.3%
Operating Lease, Liability 315K USD -28.8%
Depreciation 175K USD +10.5%
Lessee, Operating Lease, Liability, to be Paid 555K USD -22.6%
Property, Plant and Equipment, Gross 1.06M USD 0%
Operating Lease, Liability, Current 117K USD -8.26%
Lessee, Operating Lease, Liability, to be Paid, Year Two 84.6K USD -49.3%
Lessee, Operating Lease, Liability, to be Paid, Year One 167K USD +1.74%
Operating Lease, Weighted Average Discount Rate, Percent 0.1 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 240K USD -12.5%
Lessee, Operating Lease, Liability, to be Paid, Year Three 67.7K USD -19.9%
Deferred Tax Assets, Operating Loss Carryforwards 4.56M USD +48.4%
Preferred Stock, Shares Authorized 5M shares 0%
Lessee, Operating Lease, Liability, to be Paid, Year Four 67.7K USD 0%
Operating Lease, Payments 40.8K USD -28.4%
Additional Paid in Capital 31M USD +11%
Amortization of Intangible Assets 54.4K USD -53%
Interest Expense 2.51M USD +1345%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%